Biotech stocks were starved for love on Wall Street in recent years, notwithstanding revolutionary research and the launch of novel therapies for once incurable diseases.
Not anymore. The catastrophic outbreak of Covid-19 has led to a reappraisal of the sector, even if viable treatments and vaccines seem far off. Sure, biotech stocks tanked this past month, but the iShares Nasdaq Biotechnology exchange-traded fund and other industry benchmarks have been outperforming the broader market.
What are the odds I click this and see $GILD just be honest
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: